Last $46.82 USD
Change Today -0.23 / -0.49%
Volume 774.9K
NVO On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
New York
Mexico
Frankfurt
Frankfurt
As of 3:40 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NVO) Snapshot

Open
$46.92
Previous Close
$47.05
Day High
$47.09
Day Low
$46.65
52 Week High
09/18/14 - $49.11
52 Week Low
01/6/15 - $41.72
Market Cap
124.1B
Average Volume 10 Days
1.5M
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/19/15
P/E TM
--
Dividend
$0.76
Dividend Yield
1.77%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NVO)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NVO) Details

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,957 Employees
Last Reported Date: 02/5/15
Founded in 1925

novo-nordisk a/s-spons adr (NVO) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief of Staff, Executive Vice President and ...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NVO) Key Developments

Novo Nordisk Announces Positive Phase 2 OG217SC Data for Oral Formulation of Semaglutide

Emisphere Technologies Inc. highlighted positive Phase 2 data from Eligen licensee Novo Nordisk pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.

Novo Nordisk Announces Positive Results for Phase 2 Trial with Oral Semaglutide in People with Type 2 Diabetes

Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting GLP-1 analogue semaglutide, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks.

Novo Nordisk A/S Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 11:20 AM

Novo Nordisk A/S Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 11:20 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVO:US $46.83 USD -0.22

NVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $56.88 USD -3.39
Biogen Idec Inc $424.21 USD +10.07
Bristol-Myers Squibb Co $66.03 USD +0.355
Eli Lilly & Co $70.80 USD +0.15
Reckitt Benckiser Group PLC 5,825 GBp -25.00
View Industry Companies
 

Industry Analysis

NVO

Industry Average

Valuation NVO Industry Range
Price/Earnings 28.9x
Price/Sales 8.5x
Price/Book 18.8x
Price/Cash Flow 23.2x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.